MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Acorda Therapeutics Company Profile (NASDAQ:ACOR)

Consensus Ratings for Acorda Therapeutics (NASDAQ:ACOR) (?)
Ratings Breakdown: 1 Sell Rating(s), 6 Hold Rating(s), 4 Buy Rating(s)
Consensus Rating:Hold (Score: 2.27)
Consensus Price Target: $41.78 (51.42% upside)

Analysts' Ratings History for Acorda Therapeutics (NASDAQ:ACOR)
Show:
DateFirmActionRatingPrice TargetActions
5/22/2016Leerink SwannReiterated RatingHold$31.00 -> $29.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/20/2016Cowen and CompanyReiterated RatingOutperform$65.00 -> $60.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/20/2016Evercore ISIReiterated RatingHold$32.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/30/2016Goldman SachsInitiated CoverageSell$23.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/14/2016Stifel NicolausLower Price TargetBuy$48.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/11/2016JPMorgan Chase & Co.Reiterated RatingNeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/6/2016AegisBoost Price TargetBuy$40.00 -> $52.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/31/2015Raymond JamesInitiated CoverageMarket PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/31/2015Canaccord GenuityReiterated RatingHold$32.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/22/2015MLV & Co.Set Price TargetBuy$58.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/9/2015GuggenheimInitiated CoverageNeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/22/2015Piper JaffrayInitiated CoverageNeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/13/2015Citigroup Inc.Reiterated RatingHold$46.00 -> $42.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/11/2015RBC CapitalSet Price TargetBuy$45.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/31/2014FBR & Co.Reiterated RatingOutperform$57.00 -> $59.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/30/2014MKM PartnersBoost Price TargetNeutral$31.50 -> $33.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 5/25/2014 forward)
            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha